ASCO: BeiGene, Novartis Herald Global PD-1 Contender In ESCC
Filings Approaching
Executive Summary
The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.
You may also be interested in...
Keeping Track: Takeda’s Exkivity Clears US FDA; BeiGene’s Busy Summer
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication
GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.
BeiGene’s PD-1 Remains Solid In First Global Pivotal Study
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.